Trifarotene
Trifarotene, sold under the brand name Aklief, is a drug for the topical treatment of acne vulgaris in those nine years of age and older. It is a retinoid; more specifically, it is a fourth generation selective retinoic acid receptor -γ agonist.
It was approved for medical use in the United States in 2019, but is not approved in the European Union.
